Free Trial

Vanda Pharmaceuticals (VNDA) Competitors

Vanda Pharmaceuticals logo
$4.86 +0.03 (+0.52%)
As of 02:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

VNDA vs. OPK, GERN, ZBIO, RGLS, LXRX, MYGN, EBS, RIGL, XOMA, and VSTM

Should you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include OPKO Health (OPK), Geron (GERN), Zenas BioPharma (ZBIO), Regulus Therapeutics (RGLS), Lexicon Pharmaceuticals (LXRX), Myriad Genetics (MYGN), Emergent Biosolutions (EBS), Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), and Verastem (VSTM). These companies are all part of the "biotechnology" industry.

Vanda Pharmaceuticals vs. Its Competitors

OPKO Health (NASDAQ:OPK) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

64.6% of OPKO Health shares are held by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are held by institutional investors. 49.7% of OPKO Health shares are held by insiders. Comparatively, 10.0% of Vanda Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

OPKO Health presently has a consensus target price of $2.75, suggesting a potential upside of 95.73%. Vanda Pharmaceuticals has a consensus target price of $16.50, suggesting a potential upside of 239.16%. Given Vanda Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Vanda Pharmaceuticals is more favorable than OPKO Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
OPKO Health
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
3.00
Vanda Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50

OPKO Health has a net margin of -5.66% compared to Vanda Pharmaceuticals' net margin of -21.98%. OPKO Health's return on equity of -2.85% beat Vanda Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
OPKO Health-5.66% -2.85% -1.82%
Vanda Pharmaceuticals -21.98%-8.30%-6.85%

OPKO Health has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Vanda Pharmaceuticals has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.

In the previous week, Vanda Pharmaceuticals had 3 more articles in the media than OPKO Health. MarketBeat recorded 3 mentions for Vanda Pharmaceuticals and 0 mentions for OPKO Health. OPKO Health's average media sentiment score of 0.00 equaled Vanda Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
OPKO Health Neutral
Vanda Pharmaceuticals Neutral

Vanda Pharmaceuticals has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OPKO Health$713.10M1.56-$53.22M-$0.07-20.07
Vanda Pharmaceuticals$201.35M1.42-$18.90M-$0.75-6.49

Summary

OPKO Health beats Vanda Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Vanda Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VNDA vs. The Competition

MetricVanda PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$286.71M$3.07B$5.68B$9.50B
Dividend YieldN/A2.44%4.05%3.99%
P/E Ratio-6.4920.8227.9220.01
Price / Sales1.42249.55396.7382.92
Price / CashN/A41.9636.1958.45
Price / Book0.538.328.665.83
Net Income-$18.90M-$55.19M$3.24B$258.22M
7 Day Performance0.10%5.31%3.38%2.18%
1 Month Performance8.11%17.91%10.91%12.26%
1 Year Performance-21.15%7.33%35.23%21.18%

Vanda Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VNDA
Vanda Pharmaceuticals
4.6074 of 5 stars
$4.87
+0.5%
$16.50
+239.2%
-23.2%$286.71M$201.35M-6.49290News Coverage
Upcoming Earnings
OPK
OPKO Health
3.6267 of 5 stars
$1.40
+3.7%
$2.75
+96.4%
-0.3%$1.07B$713.10M-20.002,997
GERN
Geron
3.4285 of 5 stars
$1.23
-0.8%
$4.61
+274.9%
-71.2%$789.78M$76.99M-5.8670Analyst Revision
ZBIO
Zenas BioPharma
1.1236 of 5 stars
$14.29
+4.1%
$36.67
+156.6%
N/A$574.38M$5M0.00N/A
RGLS
Regulus Therapeutics
1.7461 of 5 stars
$8.16
flat
$8.50
+4.2%
N/A$564.92MN/A-11.1830
LXRX
Lexicon Pharmaceuticals
2.578 of 5 stars
$1.23
flat
$3.67
+198.1%
-45.5%$444.64M$31.08M0.00140Upcoming Earnings
Gap Up
MYGN
Myriad Genetics
4.5114 of 5 stars
$4.45
-0.4%
$14.38
+223.2%
-83.1%$412.03M$837.60M0.002,700
EBS
Emergent Biosolutions
4.3479 of 5 stars
$6.93
+0.0%
$14.33
+106.8%
-38.7%$376.14M$1.04B-2.562,420Positive News
RIGL
Rigel Pharmaceuticals
3.2325 of 5 stars
$19.59
+4.2%
$36.40
+85.8%
+100.1%$336M$179.28M9.08160Positive News
XOMA
XOMA Royalty
3.939 of 5 stars
$25.48
-0.7%
$69.50
+172.8%
-10.2%$307.19M$28.49M0.0010
VSTM
Verastem
3.5411 of 5 stars
$5.10
-1.2%
$13.38
+162.3%
+49.0%$283.54M$10K0.0050

Related Companies and Tools


This page (NASDAQ:VNDA) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners